Please login to the form below

Not currently logged in
Email:
Password:

Authorised and branded generics set to rise by 2010

Many major pharma companies will enter the generics market by 2010 in an attempt to retain a competitive edge as their product patents run out, according to a study by market intelligence firm Cutting Edge Information.

Many major pharma companies will enter the generics market by 2010 in an attempt to retain a competitive edge as their product patents run out, according to a study by market intelligence firm Cutting Edge Information.

Pharma companies are battling with generics companies keen to step in when patents expire. One tactic is known as branded generics, where a company markets a generic version of its own brand in the hope that the brand and company association will give its generic version an edge over the competition.

Other companies are negotiating license-to-distribute agreements with generics manufacturers instead of competing with them directly. This is also expected to become a more common place practice in the future ­ the industry expects to see a 33 per cent increase in authorised generics by 2010.

In many cases, as with Pfizer's Greenstone, a company subsidiary springs up to fill the role of branded generics manufacturer.

According to Cutting Edge Information's study, Combating Generics 2008: Counter Generics Strategy, Planning and Execution, the industry expects a 75 per cent increase in generic subsidiaries between now and 2010.

"Both branded generics and authorised generics are becoming more common industry practices. In fact, half of the companies in our survey plan to employ one or both of these methods by the end of 2010," said research team leader Eric Bolesh.

Twenty-four pharma companies were profiled in the study, including Pfizer, AstraZeneca, GlaxoSmithKline, Novartis, sanofi-aventis and Roche.

14th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics